Human glutathione peroxidase-6

• US 6,231,853 B1
• Filed: 06/01/1998
• Issued: 05/15/2001
• Est. Priority Date: 06/01/1998
• Status: Expired due to Fees

• Current Assignee: Incyte Pharmaceuticals, Inc.
• Original Assignee: Incyte Pharmaceuticals, Inc.
• Inventors: Patterson, Chandra, Hillman, Jennifer L., Corley, Neil C.
• Primary Examiner(s): Bansal, Geetha P.
• Application Number:
  US09/088,549
• Time in Patent Office: 1,079 Days
• Field of Search: 530/350, 424/94.1, 424/94.4, 514/12, 435/192
• US Class Current: 424/94.4
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 9/0065 acting on hydrogen peroxide as acceptor (1.11)
• CPC Class Codes: C12Y 111/01009 Glutathione peroxidase (1.11.1.9)

Abstract

The invention provides a human glutathione peroxidase (GPx6) and polynucleotides which identify and encode GPx6. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of GPx6.

Claims

1. A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:

1.

2. A composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

3. A polypeptide of claim 1 consisting of the amino acid sequence of SEQ ID NO:

1.

4. A polypeptide fragment consisting of at least 15 contiguous amino acids of the polypeptide of claim 3, wherein said polypeptide fragment exhibits glutathione peroxidase activity.

5. A composition comprising the polypeptide of claim 4 in conjunction with a suitable pharmaceutical carrier.

6. A purified polypeptide comprising a polypeptide sequence having at least 90% amino acid sequence identity to the sequence of the polypeptide of claim 4, wherein said purified polypeptide exhibits glutathione peroxidase activity.

7. A composition comprising the polypeptide of claim 6 conjunction with a suitable pharmaceutical carrier.